Found: 41
Select item for more details and to access through your institution.
Real-World Use of Fedratinib for Myelofibrosis Following Prior Ruxolitinib Failure: Patient Characteristics, Treatment Patterns, and Clinical Outcomes.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2024, v. 24, n. 2, p. 122, doi. 10.1016/j.clml.2023.09.008
- By:
- Publication type:
- Article
Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes.
- Published in:
- Oncologist, 2023, v. 28, n. 10, p. 901, doi. 10.1093/oncolo/oyad114
- By:
- Publication type:
- Article
MOMENTUM: Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor.
- Published in:
- Journal of Oncology Navigation & Survivorship, 2022, v. 13, n. 11, p. 377
- By:
- Publication type:
- Article
Thrombocytopenic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor in a Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) (MOMENTUM).
- Published in:
- Journal of Oncology Navigation & Survivorship, 2022, v. 13, n. 11, p. 388
- By:
- Publication type:
- Article
The ABNL-MARRO 001 study: a phase 1–2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes.
- Published in:
- BMC Cancer, 2022, v. 22, n. 1, p. 1, doi. 10.1186/s12885-022-10073-w
- By:
- Publication type:
- Article
The ABNL-MARRO 001 study: a phase 1-2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes.
- Published in:
- Acta Haematologica, 2022, v. 145, n. 4, p. 448, doi. 10.1159/000520440
- By:
- Publication type:
- Article
Disease and Clinical Characteristics of Patients With a Clinical Diagnosis of Myelofibrosis Enrolled in the MOST Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 7, p. e1, doi. 10.1016/j.clml.2022.02.001
- By:
- Publication type:
- Article
Treatment Patterns, Health Care Resource Utilization, and Cost in Patients with Myelofibrosis in the United States.
- Published in:
- Oncologist, 2022, v. 27, n. 3, p. 228, doi. 10.1093/oncolo/oyab058
- By:
- Publication type:
- Article
Poster: MPN-356: Transfusion Independence is Associated with Improved Overall Survival in Myelofibrosis Patients Receiving Momelotinib.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S231, doi. 10.1016/S2152-2650(21)01456-7
- By:
- Publication type:
- Article
Poster: MPN-127: Add-On Parsaclisib (a PI3Kδ Inhibitor) in Patients with Myelofibrosis and Suboptimal Response to Ruxolitinib: Interim Analysis from a Phase 2 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S232, doi. 10.1016/S2152-2650(21)01457-9
- By:
- Publication type:
- Article
Poster: MPN-038: PACIFICA: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary or Secondary Myelofibrosis and Severe Thrombocytopenia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S235, doi. 10.1016/S2152-2650(21)01480-4
- By:
- Publication type:
- Article
MPN-038: PACIFICA: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary or Secondary Myelofibrosis and Severe Thrombocytopenia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S352, doi. 10.1016/S2152-2650(21)01815-2
- By:
- Publication type:
- Article
MPN-127: Add-On Parsaclisib (a PI3K5 Inhibitor) in Patients with Myelofibrosis and Suboptimal Response to Ruxolitinib: Interim Analysis from a Phase 2 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S354, doi. 10.1016/S2152-2650(21)01819-X
- By:
- Publication type:
- Article
MPN-356: Transfusion Independence is Associated with Improved Overall Survival in Myelofibrosis Patients Receiving Momelotinib.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S364, doi. 10.1016/S2152-2650(21)01836-X
- By:
- Publication type:
- Article
Real-World Outcomes of Ruxolitinib Treatment for Polycythemia Vera.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Treatment Patterns and Blood Counts in Patients With Polycythemia Vera Treated With Hydroxyurea in the United States: An Analysis From the REVEAL Study.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Patient-Reported Outcomes in Myelodysplastic Syndromes: the Move from Life Span to Health Span.
- Published in:
- Current Hematologic Malignancy Reports, 2020, v. 15, n. 2, p. 149, doi. 10.1007/s11899-020-00562-9
- By:
- Publication type:
- Article
The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Correction to: The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Symptom Burden and Blood Counts in Patients With Polycythemia Vera in the United States: An Analysis From the REVEAL Study.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Low-Dose Lenalidomide After Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation With Bortezomib as Graft-Versus-Host Disease Prophylaxis in High-Risk Multiple Myeloma.
- Published in:
- 2019
- By:
- Publication type:
- letter
Ruxolitinib Rechallenge Can Improve Constitutional Symptoms and Splenomegaly in Patients With Myelofibrosis: A Case Series.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Distinct Genomic Associations to Predict Acute Myeloid Leukemia (AML) Progression from Myelodysplastic Syndromes (MDS).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S261, doi. 10.1016/j.clml.2018.07.172
- By:
- Publication type:
- Article
Mutational Landscape of Therapy-Related Myeloid Neoplasms.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S263, doi. 10.1016/j.clml.2018.07.177
- By:
- Publication type:
- Article
TP53 Mutations in Myeloid Neoplasms and Clonal Hematopoiesis of Indeterminate Potential following Cytotoxic Therapy for Antecedent Malignancy.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S264, doi. 10.1016/j.clml.2018.07.178
- By:
- Publication type:
- Article
Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia.
- Published in:
- American Journal of Hematology, 2018, v. 93, n. 2, p. E49, doi. 10.1002/ajh.24980
- By:
- Publication type:
- Article
Efficacy of Standard Dose R-CHOP Alternating With R-HDAC Followed by Autologous Hematopoietic Cell Transplantation as Initial Therapy of Mantle Cell Lymphoma, a Single-Institution Experience.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study.
- Published in:
- British Journal of Haematology, 2017, v. 179, n. 5, p. 781, doi. 10.1111/bjh.14954
- By:
- Publication type:
- Article
Social Media in Hematology in 2017: Dystopia, Utopia, or Somewhere In-between?
- Published in:
- Current Hematologic Malignancy Reports, 2017, v. 12, n. 6, p. 582, doi. 10.1007/s11899-017-0424-8
- By:
- Publication type:
- Article
Patient-Reported Outcomes in Myelodysplastic Syndromes and MDS/MPN Overlap Syndromes: Stepping Onto the Stage with Changing Times.
- Published in:
- Current Hematologic Malignancy Reports, 2017, v. 12, n. 5, p. 455, doi. 10.1007/s11899-017-0406-x
- By:
- Publication type:
- Article
The association of histologic grade with acute graft-versus-host disease response and outcomes.
- Published in:
- American Journal of Hematology, 2017, v. 92, n. 7, p. 683, doi. 10.1002/ajh.24749
- By:
- Publication type:
- Article
Polycythemia Vera Management and Challenges in the Community Health Setting.
- Published in:
- Oncology, 2017, v. 92, n. 4, p. 179, doi. 10.1159/000454953
- By:
- Publication type:
- Article
Let's talk about sex[uality]-related symptom burden in myeloproliferative neoplasms.
- Published in:
- 2016
- By:
- Publication type:
- editorial
Delayed globin synthesis leads to excess heme and the macrocytic anemia of Diamond Blackfan anemia and del(5q) myelodysplastic syndrome.
- Published in:
- Science Translational Medicine, 2016, v. 8, n. 338, p. 1, doi. 10.1126/scitranslmed.aaf3006
- By:
- Publication type:
- Article
Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera?
- Published in:
- Oncologist, 2016, v. 21, n. 4, p. 475, doi. 10.1634/theoncologist.2015-0380
- By:
- Publication type:
- Article
The graceful exit or reluctant demise of the older adult with acute myeloid leukemia.
- Published in:
- 2015
- By:
- Publication type:
- Editorial
I Walk the Other Line: Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndromes.
- Published in:
- Current Hematologic Malignancy Reports, 2014, v. 9, n. 4, p. 400, doi. 10.1007/s11899-014-0233-2
- By:
- Publication type:
- Article
Last Marrow Standing: Bone Marrow Transplantation for Acquired Bone Marrow Failure Conditions.
- Published in:
- Current Hematologic Malignancy Reports, 2012, v. 7, n. 4, p. 292, doi. 10.1007/s11899-012-0138-x
- By:
- Publication type:
- Article
To Transplant or Not to Transplant for Adult Acute Myeloid Leukemia: An Ever-Evolving Decision.
- Published in:
- Clinical Advances in Hematology & Oncology, 2012, v. 10, n. 10, p. 1
- By:
- Publication type:
- Article
Functional alterations in protein kinase C beta II expression in melanoma.
- Published in:
- Pigment Cell & Melanoma Research, 2010, v. 23, n. 2, p. 216, doi. 10.1111/j.1755-148X.2009.00664.x
- By:
- Publication type:
- Article